Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2610-2615

  Iqbal, S ^a   Goldman, B ^b   Fenoglio Preiser, C M ^c   Lenz, H J ^a   Zhang, W ^a   Danenberg, K D ^d   Shibata, S I ^e   Blanke, C D ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d Response Genetics Inc   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

EGFR; Gastric cancer; HER2; Lapatinib

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 8; LAPATINIB; TUMOR MARKER; VASCULOTROPIN;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ARTICLE; BRAIN ISCHEMIA; CANCER MORTALITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG FATALITY; FATIGUE; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80054057131     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr021     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; CD004064.
3. Yoshida K, Tsujino T, Yasui W et al. Induction of growth factor-receptor and metalloproteinase genes by epidermal growth factor and/or transforming growth factor-alpha in human gastric carcinoma cell line MKN-28. Jpn J Cancer Res 1990; 81: 793-798.
4. Piontek M, Hengels KJ. The EGF receptor and stomach cancer. Z Gastroenterol 1993; 31(Suppl 5): 18-20.
5. Teramoto T, Onda M, Tokunaga A, Asano G. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer 1996; 77: 1639-1645.
6. Kopp R, Ruge M, Rothbauer E et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002; 22: 1161-1167.
7. Yasui W, Sumiyoshi H, Hata J et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988; 48: 137-141.
8. He SW, Guo LY, Li JQ. Clinical study on epidermal growth factor and its receptor in human gastric cancer. Zhonghua Yi Xue Za Zhi 1994; 74: 413-415, 455.
9. Tokunaga A, Onda M, Okuda T et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995; 75: 1418-1425.
10. Risio M, De Rosa G, Sarotto I et al. HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 2003; 23: 1381-1387.
11. Pinto-de-Sousa J, David L, Almeida R et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10: 247-256.
12. Oshima CT, Lanzoni VP, Iriya K, Forones NM. C-erbB-2 oncoprotein in gastric carcinoma: correlation with clinical stage and prognosis. Int J Biol Markers 2001; 16: 250-254.
13. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
14. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
15. Wainberg ZA, Anghel A, Desai AJ et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010; 16: 1509-1519.
16. Kim JW, Kim HP, Im SA et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008; 272: 296-306.
17. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731-738.
18. Shewchuk L, Hassell A, Wisely B et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: x-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 2000; 43: 133-138.
19. Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 1992; 11: 853-862.
20. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927.
21. Enzinger PC, Burtness B, Hollis D et al. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010; 28.
22. Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18: 510-517.
23. Arnold D, Hohler T, Dittrich C et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI group. Ann Oncol 2008; 19: 1442-1449.
24. Rusnak DW, Alligood KJ, Mullin RJ et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007; 40: 580-594.
25. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
26. Vogel C, Cobleigh MA, Tripathy D et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. A preliminary report. Eur J Cancer 2001; 37(Suppl 1): 25-29.
27. Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-1333.
28. Tanizaki J, Okamoto I, Takezawa K et al. Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 2010; 9: 1198-1207.
29. Berenberg JL, Tangen C, Macdonald JS et al. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. Cancer 1995; 76: 715-719.